Antiviral drug

Global Antiviral Drugs Market 2020-2024: Insights & Forecast with Potential Impact of COVID-19 - Leading Players are J&J, Merck & Co., AbbVie, Bristol-Myer Squibb, Gilead Sciences and Cipla

Friday, November 27, 2020 - 2:30pm

DUBLIN, Nov. 27, 2020 /PRNewswire/ -- The "Global Antiviral Drugs Market (By Type, Application & Region): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 27, 2020 /PRNewswire/ -- The "Global Antiviral Drugs Market (By Type, Application & Region): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.
  • The global antiviral drugs market is expected to reach US$ 70.95 billion in 2024, increasing at a CAGR of 2.10%, for the duration of 2020-2024.
  • However, the market growth would be challenged by high cost involves in drug development, threats associated with drug counterfeiting and stringent government regulations.
  • The global antiviral drugs market is fragmented into branded drugs and generic drugs.

Atea Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference

Wednesday, November 25, 2020 - 12:00pm

BOSTON, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announced that management will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on Thursday, December 3, 2020 at 12:35 p.m.

Key Points: 
  • BOSTON, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announced that management will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on Thursday, December 3, 2020 at 12:35 p.m.
  • A live webcast of the presentation will be available on the Companys website at www.ateapharma.com .
  • A replay of the webcast will be available for 90 days following the presentation.
  • Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases.

Venatorx Pharmaceuticals Names Robert Waltermire, Ph.D. Senior Vice President, CMC

Tuesday, November 24, 2020 - 3:00pm

Venatorx Pharmaceuticals today announced that Robert Waltermire, Ph.D. has joined the Company as Senior Vice President, Chemistry, Manufacturing and Controls (CMC).

Key Points: 
  • Venatorx Pharmaceuticals today announced that Robert Waltermire, Ph.D. has joined the Company as Senior Vice President, Chemistry, Manufacturing and Controls (CMC).
  • Robs broad experience, from pre-clinical and clinical development through large scale manufacturing processes, will be invaluable for our antibiotic and antiviral programs.
  • Prior to joining Venatorx, Dr. Waltermire was Senior Vice President, Product Development at Palatin Technologies where he led a global team to deliver on all aspects of the generation of knowledge and product for both clinical development and commercial sale.
  • Venatorx Pharmaceuticals is a private pharmaceutical company focused on improving health outcomes for patients with multi-drug-resistant bacterial infections and hard-to-treat viral infections.

FDA Expands Approval of Influenza Treatment to Post-Exposure Prevention

Monday, November 23, 2020 - 5:41pm

Xofluza, previously available only in tablet form, is also now available as granules for mixing in water.

Key Points: 
  • Xofluza, previously available only in tablet form, is also now available as granules for mixing in water.
  • Flu is a contagious respiratory illness caused by influenza viruses .
  • Treating flu patients with antiviral drugs within 48 hours of their becoming sick can reduce symptoms and duration of the illness.
  • The FDA granted the approval of Xofluza to Genentech USA, Inc.

Merck Submits Applications for Licensure of V114, the Company’s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults to the U.S. FDA and European Medicines Agency

Monday, November 23, 2020 - 11:47am

These submissions for V114 help bring us closer to offering more options to help protect against pneumococcal disease.

Key Points: 
  • These submissions for V114 help bring us closer to offering more options to help protect against pneumococcal disease.
  • V114 is Mercks investigational 15-valent pneumococcal conjugate vaccine candidate for the prevention of pneumococcal disease in adults and children.
  • For more than 100 years, Merck has contributed to the discovery and development of novel medicines and vaccines to combat infectious diseases.
  • In addition to a combined portfolio of vaccines and antibacterial, antiviral and antifungal medicines, Merck has multiple programs that span discovery through late-stage development.

Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19

Sunday, November 22, 2020 - 1:17am

The safety and effectiveness of this investigational therapy for use in the treatment of COVID-19 continues to be evaluated.

Key Points: 
  • The safety and effectiveness of this investigational therapy for use in the treatment of COVID-19 continues to be evaluated.
  • A benefit of casirivimab and imdevimab treatment has not been shown in patients hospitalized due to COVID-19.
  • Authorizing these monoclonal antibody therapies may help outpatients avoid hospitalization and alleviate the burden on our health care system," said FDA Commissioner Stephen M. Hahn, M.D.
  • Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability to fight off harmful pathogens such as viruses.

Clear Creek Bio Doses First Patient in Phase 2 Outpatient Study of Brequinar to Treat COVID-19

Friday, November 20, 2020 - 4:08pm

Clear Creek Bio, Inc. announced today that the company has dosed the first patient in the CRISIS2 study, a Phase 2 clinical study evaluating brequinar for the treatment of COVID-19.

Key Points: 
  • Clear Creek Bio, Inc. announced today that the company has dosed the first patient in the CRISIS2 study, a Phase 2 clinical study evaluating brequinar for the treatment of COVID-19.
  • Theres an exceptional need for oral antiviral treatments that are suitable for outpatient treatment, and we are pleased to advance brequinar into a Phase 2 clinical trial for the treatment of COVID-19, said Vikram Sheel Kumar, M.D., Chief Executive Officer of Clear Creek Bio.
  • We believe brequinars unique drug profile, with oral bioavailability and high potency, supports its development as an oral, once-daily treatment for COVID-19.
  • Clear Creek Bio is a private biotech company focused on developing novel therapies to address infectious disease and cancer.

Sosei Heptares' COVID-19 Program Identifies Potent Broad Spectrum Anti-Viral Small Molecules for Further Development

Friday, November 20, 2020 - 9:05am

Sosei Heptares has successfully designed three distinct series of compounds with attractive anti-viral drug-like properties and advanced the most promising molecules.

Key Points: 
  • Sosei Heptares has successfully designed three distinct series of compounds with attractive anti-viral drug-like properties and advanced the most promising molecules.
  • We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology and inflammatory diseases.
  • "Sosei Heptares" is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565).
  • Sosei, Heptares, the logo and StaR are trademarks of Sosei Group companies.

Europe Anti-Viral Therapies Markets, 2019-2020 & 2027 - Growing Emphasis on Launching Anti-Viral Agents

Thursday, November 19, 2020 - 8:15pm

The Europe anti-viral therapies market is expected to reach US$ 21,122.66 million by 2027 from US$ 11,401.67 million in 2019; it is estimated to grow at a CAGR of 8.1% during 2020-2027.

Key Points: 
  • The Europe anti-viral therapies market is expected to reach US$ 21,122.66 million by 2027 from US$ 11,401.67 million in 2019; it is estimated to grow at a CAGR of 8.1% during 2020-2027.
  • Additionally, strong pipeline of anti-viral drugs, and growing emphasis on launching anti-viral agents are likely to fuel the growth of the Europe anti-viral therapies market during the forecast period.
  • High cost of drug development is a key factor restraining the growth of the market.
  • In 2019, the branded drugs segment accounted for a larger share of the Europe antiviral therapies market.

Anti-COVID nasal spray formulated at University of Birmingham, UK is 'ready for use in humans'

Thursday, November 19, 2020 - 1:00pm

This means that the normal procedures to take a new product to market are simplified, and the nasal spray could be commercially available very quickly.

Key Points: 
  • This means that the normal procedures to take a new product to market are simplified, and the nasal spray could be commercially available very quickly.
  • The formulation consists of an antiviral agent, carrageenan, and a gellan polysaccharide, both of which are already manufactured to pharmaceutical grade.
  • A pre-print study (not yet peer-reviewed) describes cell culture that tested the ability of the formulation to inhibit COVID-19 infection.
  • The research team screened FDA-approved polymers for their muco-adhesive properties and their ability to 'plume' when sprayed using a typical nasal spray applicator.